Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the USA / NCT07852650
Recruiting Phase 1/2

Digital STEADI Efficacy

NCT07852650 · tracked via the Priya Life Science USA tracker
Sponsor
Friendi.fi Corporation
Phase
Phase 1/2
Started
2026-09-04
Last updated
2026-10-01

Condition(s) studied

FallMild Cognitive Impairment (MCI)Aging

Investigational drug(s) / intervention(s)

Digital STEADI-1STEADI Standard of CareDigital STEADI-2Attentional control

Digital STEADI-1: STEADI fall risk screening, monitoring and exercise program delivered and coordinated via tablet-based avatar.

STEADI Standard of Care: STEADI fall risk screening, monitoring, and exercise program delivered and coordinated via paper and pencil and humans.

Digital STEADI-2: STEADI fall risk screening, monitoring and exercise program delivered and coordinated via SMS chat.

Attentional control: Receiving CDC Healthy Living content unrelated to fall prevention plus usual geriatric care.

Study summary

The aging of the U.S. population, combined with health care workforce shortages and insufficient access to effective fall prevention and exercise programs, has contributed to a high burden of fall-related injuries in older adults, especially in those with Mild Cognitive Impairment (MCI), a precursor of Alzheimer's dementia (AD) and related dementias (ADRD). There is an urgent need for scalable, evidence-based interventions that can be delivered efficiently in the home setting. This study aims to evaluate the efficacy and impact of a comprehensive digital fall prevention program (Digital STEADI) delivered through a technology platform with two conversational agents that leverage generative artificial intelligence (gen-AI) with human oversight to increase program access, enhance adherence to clinical fall prevention protocols and best practices, and reduce fall risk among community-dwelling older adults.

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Montreal Cognitive Assessment (MoCA) score between 26 and 30 * Able to walk independently with or without an assistive device. * Able to rise independently from a standard desk or dining room chair without arms. * Live independently in a non-institutional or senior community setting. * Able to speak, hear and understand English * Have 20/40 vision from 10 ft with or without correction (e.g., glasses) * Willing to participate in the requirements of the research program. * Able to meet in a physical study location on Emory campus. * Screen positive for fall risk per the Stay Independent screener. Exclusion Criteria: * acute medical illness requiring hospitalization. * hospitalized in the past 1 month. * diagnosed with dementia (ADRD) or a neurodegenerative disease other than MCI (e.g., Parkinson's, multiple sclerosis). * uncontrolled congestive heart failure (requiring hospitalization in the past year and/or unable to the equivalent of one city block). * history of hospitalization for stroke in the past 1 year. * inability to perform study procedures.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Emory University School of Medicine Atlanta Georgia Recruiting

More Friendi.fi Corporation trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07852650 on ClinicalTrials.gov ↗ ← All trials in the USA